English | 简体中文 | LP ACCESS

About artrix

This author has not yet filled in any details.
So far artrix has created 70 blog entries.

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older2022-08-03T22:23:46-07:00

Avistone Pharmaceuticals Secures $200M Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital

Avistone Pharmaceuticals Secures $200M Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital2022-03-09T22:05:12-08:00

Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market 

Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market 2022-03-09T21:58:39-08:00

Aadi Bioscience Announces FDA Approval FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Aadi Bioscience Announces FDA Approval FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)2022-03-09T21:51:12-08:00

Palo Alto
Global Headquarters

Beijing
 

Shanghai 
 

Taipei  
 

Hong Kong   
 

Email: info@vivocapital.com
Vivo Capital®, SEC registered, effective 6/19/2014. All rights reserved.
Go to Top